Cardinal Health Inc. reported a strong fourth-quarter performance for fiscal year 2024, with adjusted EPS rising 29% year over year to $1.84, surpassing analyst expectations. The company achieved total sales of $59.87 billion, a 12% increase, driven primarily by growth in its pharmaceutical segment. Cardinal Health has raised its fiscal year 2025 adjusted EPS guidance to between $7.55 and $7.70, up from a previous estimate of at least $7.50. Despite this positive outlook, the company anticipates a 4% to 6% decline in revenue from its pharmaceutical unit due to the loss of contracts with UnitedHealth Group's OptumRx. Analysts have mixed views on Cardinal Health's stock, with a consensus rating of Moderate Buy. Overall, the company remains optimistic about its future growth, bolstered by strong demand for specialty medicines and strategic financial management.